ReviewOncogene2014
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Review in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- A Pax7::Foxo1 conditional mouse strain.Skeletal muscle · 2026Article
- HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.Cell death discovery · 2024Article
- MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Nature communications · 2023Article
- Stakeholders' views on drug development: the congenital disorders of glycosylation community perspective.Orphanet journal of rare diseases · 2022Article
- SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.Cell reports · 2022Article
- MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression.Frontiers in oncology · 2022Article
- SNAI2-Mediated Repression ofCancer research · 2021Article
- Review
- Defining the Extracellular Matrix of Rhabdomyosarcoma.Frontiers in oncology · 2021Article
- Prospective use of the single-mouse experimental design for the evaluation of PLX038A.Cancer chemotherapy and pharmacology · 2020Article
- c-Myb regulates tumorigenic potential of embryonal rhabdomyosarcoma cells.Scientific reports · 2019Article
- Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors.Molecular cancer research : MCR · 2019Article
- SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.Cell death & disease · 2018Article
- Article
- EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.PloS one · 2017Article
- Synergistic Antitumour Properties ofJournal of immunology research · 2017Article
- Rare cancers: Challenges & issues.The Indian journal of medical research · 2017Review
- Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Nature reviews. Cancer · 2015Review
- Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.Frontiers in oncology · 2015Review
- Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell Lines.Frontiers in oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Rare diseases typically affect fewer than 200,000 patients annually, yet because thousands of rare diseases exist, the cumulative impact is millions of patients worldwide. Every form of childhood cancer qualifies as a rare disease-including the childhood muscle cancer, rhabdomyosarcoma (RMS). The next few years promise to be an exceptionally good era of opportunity for public-private collaboration for rare and childhood cancers. Not only do certain governmental regulation advantages exist, but these advantages are being made permanent with special incentives for pediatric orphan drug-product development. Coupled with a growing understanding of sarcoma tumor biology, synergy with pharmaceutical muscle disease drug-development programs, and emerging publically available preclinical and clinical tools, the outlook for academic-community-industry partnerships in RMS drug development looks promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.